TrialInternational journal of clinical oncology2017

A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).

Koji Ando et al.PubMed ↗Publisher ↗

No numbers read from the abstract.